Weight-loss drugs such as Wegovy, Zepbound, and other GLP-1 medications are no longer covered for TRICARE For Life (TFL) beneficiaries as of Aug
Glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic and Mounjaro, have become popular medications for controlling diabetes and treating obesity but new Canadian research suggests they can also lead to a paradoxical side effect in the form of eye problems
These effects are often dose-related and may lessen as the body adjusts to the medication
FDA adverse event data (as of early 2025) 455+ adverse event reports linked to compounded semaglutide 320+ adverse event reports linked to compounded tirzepatide Many involved dosing errors from multidose vials, some requiring hospitalization Reports include severe nausea, vomiting, dehydration, and overdose symptoms Documented contamination, mislabeling, and counterfeit product cases 1
In the age of GLP-1 agonists, food choices still matter for health
